Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.89
ANAC's Cash to Debt is ranked lower than
68% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ANAC: 2.89 )
Ranked among companies with meaningful Cash to Debt only.
ANAC' s 10-Year Cash to Debt Range
Min: 0.48  Med: 4.13 Max: N/A
Current: 2.89
Equity to Asset 0.34
ANAC's Equity to Asset is ranked lower than
82% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ANAC: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
ANAC' s 10-Year Equity to Asset Range
Min: -11.16  Med: 0.20 Max: 0.71
Current: 0.34
-11.16
0.71
F-Score: 1
Z-Score: 25.51
M-Score: -3.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -259.46
ANAC's Operating margin (%) is ranked lower than
65% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ANAC: -259.46 )
Ranked among companies with meaningful Operating margin (%) only.
ANAC' s 10-Year Operating margin (%) Range
Min: -15647.66  Med: -174.44 Max: 537.02
Current: -259.46
-15647.66
537.02
Net-margin (%) -248.29
ANAC's Net-margin (%) is ranked lower than
65% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ANAC: -248.29 )
Ranked among companies with meaningful Net-margin (%) only.
ANAC' s 10-Year Net-margin (%) Range
Min: -15368.22  Med: -184.67 Max: 492.02
Current: -248.29
-15368.22
492.02
ROE (%) -97.40
ANAC's ROE (%) is ranked lower than
80% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. ANAC: -97.40 )
Ranked among companies with meaningful ROE (%) only.
ANAC' s 10-Year ROE (%) Range
Min: -599.54  Med: -111.72 Max: 134.29
Current: -97.4
-599.54
134.29
ROA (%) -45.00
ANAC's ROA (%) is ranked lower than
66% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. ANAC: -45.00 )
Ranked among companies with meaningful ROA (%) only.
ANAC' s 10-Year ROA (%) Range
Min: -216.67  Med: -52.31 Max: 75.94
Current: -45
-216.67
75.94
ROC (Joel Greenblatt) (%) -5246.64
ANAC's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. ANAC: -5246.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANAC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8736.49  Med: -1203.86 Max: 6087.56
Current: -5246.64
-8736.49
6087.56
Revenue Growth (3Y)(%) -12.00
ANAC's Revenue Growth (3Y)(%) is ranked lower than
62% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ANAC: -12.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANAC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5  Med: -34.10 Max: 467.9
Current: -12
-70.5
467.9
EBITDA Growth (3Y)(%) 10.60
ANAC's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ANAC: 10.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANAC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.1  Med: -27.80 Max: 10.6
Current: 10.6
-63.1
10.6
EPS Growth (3Y)(%) 6.40
ANAC's EPS Growth (3Y)(%) is ranked higher than
65% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ANAC: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANAC' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -56.80 Max: 6.4
Current: 6.4
0
6.4
» ANAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ANAC Guru Trades in Q2 2014

Jim Simons 207,578 sh (+534.80%)
» More
Q3 2014

ANAC Guru Trades in Q3 2014

Chuck Royce 340,500 sh (New)
Steven Cohen 1,554,600 sh (New)
Jim Simons 109,358 sh (-47.32%)
» More
Q4 2014

ANAC Guru Trades in Q4 2014

Paul Tudor Jones 12,285 sh (New)
Steven Cohen 1,564,343 sh (+0.63%)
Chuck Royce 340,500 sh (unchged)
Jim Simons Sold Out
» More
Q1 2015

ANAC Guru Trades in Q1 2015

Steven Cohen Sold Out
Paul Tudor Jones 10,755 sh (-12.45%)
Chuck Royce 284,500 sh (-16.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ANAC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 1428.57
ANAC's Forward P/E is ranked lower than
99% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. ANAC: 1428.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 86.66
ANAC's P/B is ranked lower than
99% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ANAC: 86.66 )
Ranked among companies with meaningful P/B only.
ANAC' s 10-Year P/B Range
Min: 2.44  Med: 10.10 Max: 177.5
Current: 86.66
2.44
177.5
P/S 200.32
ANAC's P/S is ranked lower than
90% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. ANAC: 200.32 )
Ranked among companies with meaningful P/S only.
ANAC' s 10-Year P/S Range
Min: 0.3  Med: 18.93 Max: 207.61
Current: 200.32
0.3
207.61
Current Ratio 4.58
ANAC's Current Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. ANAC: 4.58 )
Ranked among companies with meaningful Current Ratio only.
ANAC' s 10-Year Current Ratio Range
Min: 0.4  Med: 2.52 Max: 9.58
Current: 4.58
0.4
9.58
Quick Ratio 4.52
ANAC's Quick Ratio is ranked higher than
53% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ANAC: 4.52 )
Ranked among companies with meaningful Quick Ratio only.
ANAC' s 10-Year Quick Ratio Range
Min: 0.4  Med: 2.52 Max: 9.58
Current: 4.52
0.4
9.58
Days Inventory 291.15
ANAC's Days Inventory is ranked lower than
86% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. ANAC: 291.15 )
Ranked among companies with meaningful Days Inventory only.
ANAC' s 10-Year Days Inventory Range
Min: 576.58  Med: 576.58 Max: 576.58
Current: 291.15
Days Sales Outstanding 37.37
ANAC's Days Sales Outstanding is ranked higher than
72% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ANAC: 37.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANAC' s 10-Year Days Sales Outstanding Range
Min: 1.43  Med: 34.47 Max: 365
Current: 37.37
1.43
365

Valuation & Return

vs
industry
vs
history
Price/Net Cash 197.71
ANAC's Price/Net Cash is ranked lower than
98% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. ANAC: 197.71 )
Ranked among companies with meaningful Price/Net Cash only.
ANAC' s 10-Year Price/Net Cash Range
Min: 2.95  Med: 10.21 Max: 162.25
Current: 197.71
2.95
162.25
Price/Net Current Asset Value 148.77
ANAC's Price/Net Current Asset Value is ranked lower than
98% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. ANAC: 148.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANAC' s 10-Year Price/Net Current Asset Value Range
Min: 2.8  Med: 9.91 Max: 57.78
Current: 148.77
2.8
57.78
Price/Tangible Book 89.98
ANAC's Price/Tangible Book is ranked lower than
99% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. ANAC: 89.98 )
Ranked among companies with meaningful Price/Tangible Book only.
ANAC' s 10-Year Price/Tangible Book Range
Min: 2.67  Med: 8.92 Max: 93.17
Current: 89.98
2.67
93.17
Price/Median PS Value 10.87
ANAC's Price/Median PS Value is ranked lower than
97% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. ANAC: 10.87 )
Ranked among companies with meaningful Price/Median PS Value only.
ANAC' s 10-Year Price/Median PS Value Range
Min: 0.02  Med: 1.02 Max: 4.25
Current: 10.87
0.02
4.25
Earnings Yield (Greenblatt) (%) -1.34
ANAC's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ANAC: -1.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANAC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.34  Med: 12.25 Max: 18.9
Current: -1.34
-1.34
18.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44A.Germany,
Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.
» More Articles for ANAC

Headlines

Articles On GuruFocus.com
Anacor Pharmaceuticals’ Q4 Was A Solid One For Investors Mar 16 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
3 Great Dividend Stocks at All-Time Highs Aug 19 2013 
Weekly CFO Buys Highlight Aug 19 2013 
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. Geoffrey Parker Bought 43,046 Shares Jun 20 2013 
This Week's Top Insider Buys Jun 19 2013 
comment on ANAC Mar 15 2013 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: GSVC, SHO, YAVY, CMCSA, ANAC May 16 2011 

More From Other Websites
Alexion Misses on Earnings in Q2, 2015 Outlook Revised - Analyst Blog Jul 30 2015
Anacor Pharmaceuticals Outperforms the Market Jul 30 2015
Will Anacor Pharmaceuticals (ANAC) Continue to Surge Higher? - Tale of the Tape Jul 29 2015
Anacor Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 6, 2015 Jul 23 2015
Anacor Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 6, 2015 Jul 23 2015
Street Talk: UNFI, SUNE, AMGN & more Jul 21 2015
Anacor Pharma upgraded by Goldman and BofA/Merrill Jul 21 2015
Bristol-Myers' HIV-1 Drug Evotaz Gets European Approval - Analyst Blog Jul 17 2015
These Hot Healthcare Stocks Lead Palo Alto Investors’ Picks To Big Q2 Returns Jul 17 2015
Manager Of Hot New Biotech ETFs Explains The Strategy Jul 16 2015
Why This Biotech ETF Keeps Surging Jul 15 2015
The element that should keep Anacor Pharma soaring Jul 15 2015
Anacor Hits 52-Week High on Positive Atopic Dermatitis Data - Analyst Blog Jul 14 2015
Anacor May Have $2 Billion Drug Jul 14 2015
Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 55.9% - Tale of the Tape Jul 14 2015
Anacor Pharmaceutical's Positive Skin Cream Results Sends Stock Soaring - Stocks in the News Jul 13 2015
Anacor Pharmaceuticals (ANAC) Stock Spiked on Positive Phase 3 Study Results Jul 13 2015
US stocks surge on Greece deal Jul 13 2015
ANACOR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK